The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant - Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients &gt;2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO);the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury). Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in hospitalized patients &gt;12 years old who weigh &gt;40 kg;it is available under an EUA for treatment of other hospitalized patients.
An EUA for Baricitinib (Olumiant) for COVID-19